Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 sept. 2025 05h40 HE | Source: Research and Markets

Microfluidics Industry Outlook and Competition Analysis 2025-2030: A $47.7 Billion Opportunity Led by Illumina, Roche, and PerkinElmer

Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Microfluidics Market - Forecasts from 2025 to 2030" has been added to ResearchAndMarkets.com's offering. The global microfluidics market is poised...
25 sept. 2025 05h31 HE | Source: Research and Markets

Flow Cytometry Services Market Industry Trends and Global Forecasts to 2035: Mergers, Partnerships, and Technology Innovation Accelerate Growth in Flow Cytometry Services Market

Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Flow Cytometry Services Market Industry Trends and Global Forecasts to 2035: Distribution by Service, Type of Analysis based Flow Cytometric Services,...
25 sept. 2025 02h10 HE | Source: VarmX B.V.

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得日本の規制当局である医薬品医療機器総合機構 (PMDA)...
25 sept. 2025 02h10 HE | Source: VarmX B.V.

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Drug developer VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001, enabling it to go straight to Phase 3 studies in Japan.
17 sept. 2025 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for...
10 sept. 2025 09h15 HE | Source: Research and Markets

Pharmaceutical Drug Development Annual Market Review 2024-2025 | Key Shifts and Strategic Priorities for Companies Navigating Evolving Pharma Ecosystem

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Development Annual Review - 2024" report has been added to ResearchAndMarkets.com's offering.This report investigates the year...
03 sept. 2025 11h26 HE | Source: Research and Markets

U.S. Multiomics Services Market Trends Analysis Report 2025-2033 | Integrated Data Demand, Genomics & Proteomics Advances, and AI-Driven Insights Propel Growth

Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The "U.S. Multiomics Services Market Size, Share & Trends Analysis Report By Services (Research, Data Analysis), By Type (Single-cell Multiomics, Bulk...
28 août 2025 06h07 HE | Source: SAI LIFE SCIENCES LIMITED

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

HYDERABAD, India, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization...
18 août 2025 05h09 HE | Source: Research and Markets

Validation of FDA-Regulated Systems Used in Drug Development & Submissions Using AI, Machine Learning & Large Language Models such as ChatGPT - Online Training Course, August 28, 2025

Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "Validation of FDA-Regulated Systems Used in Drug Development & Submissions Using Artificial Intelligence (AI), Machine Learning (ML) & Large...
18 août 2025 01h15 HE | Source: Novartis Pharma AG

New Novartis ESC data highlights strength of cardiovascular portfolio

Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing...

Page suivante